Back to Results
First PageMeta Content
Health / Pharmaceutical Benefits Scheme / Generic drug / Prescription medication / Pricing / Pharmaceutical industry / Pharmacy / Pharmaceutical policy / Pharmaceuticals policy / Pharmaceutical sciences / Pharmacology


December[removed]Poor  pricing  progress Price  disclosure  isn’t the  answer  to  high  drug  prices Stephen Duckett and Peter Breadon
Add to Reading List

Document Date: 2014-08-04 20:26:09

Open Document

File Size: 724,88 KB

Share Result on Facebook

City

Auckland / /

Company

Wesfarmers / Partners Google National Australia Bank Origin / Creative Commons / Price / GE / Medicines Australia / /

Country

Germany / Japan / Canada / Australia / United Kingdom / New Zealand / /

Currency

USD / /

Facility

Grattan Institute Grattan Institute / Grattan Institute / After pharmacy / /

Holiday

Commonwealth Day of Australia / /

IndustryTerm

pharmaceuticals / pharmaceutical industry / pharmaceutical industry-funded reports / retail mark-ups / /

MedicalCondition

cuts / high cholesterol / mild depression / breast cancer / /

Organization

Pharmaceutical Benefits Advisory Committee / Scanlon Foundation Urbis Grattan Institute / Pharmacy Guild of Australia and Ranbaxy / Grattan Institute / European Union / Department of Health / Commonwealth Government / Pharmaceutical Benefits Pricing Authority / PBS Pharmaceutical Benefits Pricing Authority / Overview Grattan Institute / Grattan Institute Grattan Institute / Grattan Institute Support Founding / /

Person

Roy Harvey / Wyatt Healthcare / Leah Ginnivan / Peter Breadon / Jonathan Nolan / Brendan Shaw / Colin Hui / Sinclair Knight Merz / Stephen Duckett / Philip Clarke / /

Position

Health Minister / CEO of pharmaceutical industry group / Finance Minister / Health Program Director / CEO / /

Product

venlafaxine / 1mg / Lipitor / Arimidex / anastrozole / /

ProvinceOrState

Ontario / /

URL

http /

SocialTag